{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T21:56:14Z","timestamp":1759010174753},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Clinical Virology"],"published-print":{"date-parts":[[2007,1]]},"DOI":"10.1016\/j.jcv.2006.09.009","type":"journal-article","created":{"date-parts":[[2006,10,25]],"date-time":"2006-10-25T15:51:13Z","timestamp":1161791473000},"page":"32-38","source":"Crossref","is-referenced-by-count":19,"title":["Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV\/HIV coinfected patients who failed previous IFN based therapy"],"prefix":"10.1016","volume":"38","author":[{"given":"Maribel","family":"Rodr\u00edguez-Torres","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 F.","family":"Rodr\u00edguez-Orengo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos F.","family":"R\u00edos-Bedoya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Fern\u00e1ndez-Carbia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elsa","family":"Gonz\u00e1lez-Lassalle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Salgado-Mercado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Acisclo M.","family":"Marxuach-Cu\u00e9tara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jcv.2006.09.009_bib1","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jhep.2005.03.003","article-title":"Short statement of the first European consensus conference on the treatment of chronic hepatitis B and C in HIV co-infected patients","volume":"42","author":"Alberti","year":"2005","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.jcv.2006.09.009_bib2","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJM199908193410802","article-title":"The prevalence of hepatitis C virus infection in the United States 1988, through 1994","volume":"341","author":"Alter","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcv.2006.09.009_bib3","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/hep.510300409","article-title":"Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients","volume":"30","author":"Benhamou","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.jcv.2006.09.009_bib4","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1053\/jhep.2001.26517","article-title":"Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy","volume":"34","author":"Benhamou","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.jcv.2006.09.009_bib5","series-title":"Proceedings of the 55th Annual meeting of the American Association for the Study of Liver Diseases","article-title":"Reduction of the relative relapse rate by prolongation of the duration of a therapy with peginterferon alfa-2a plus ribavirin in patients with genotype 1 infection up to 72 weeks","author":"Berg","year":"2004"},{"key":"10.1016\/j.jcv.2006.09.009_bib6","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1046\/j.1365-2893.1999.00153.x","article-title":"Patients coinfected with human immunodeficiency virus and hepatitis C virus demonstrate higher levels of hepatic HCV RNA","volume":"6","author":"Bonacini","year":"1999","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jcv.2006.09.009_bib7","first-page":"2071","article-title":"Prevalence of hepatitis C and coinfection with HIV among United States veterans in the New York City metropolitan area","volume":"97","author":"Brau","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jcv.2006.09.009_bib8","unstructured":"Center for Disease Control and Prevention (CDC). 2004. Website: http:\/\/www.cdc.gov\/ncidod\/diseases\/hepatitis\/C\/fact.htm."},{"key":"10.1016\/j.jcv.2006.09.009_bib9","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1097\/00002030-199510000-00003","article-title":"High hepatitis C viremia and impaired antibody response in patients coinfected with HIV","volume":"9","author":"Cribier","year":"1995","journal-title":"AIDS"},{"key":"10.1016\/j.jcv.2006.09.009_bib10","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1053\/jhep.2001.29201","article-title":"The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study","volume":"34","author":"Di Martino","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.jcv.2006.09.009_bib11","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/00002030-200202150-00016","article-title":"HIV co infection does not compromise liver histological response to interferon therapy in patients with chronic hepatitis C","volume":"16","author":"Di Martino","year":"2002","journal-title":"AIDS"},{"issue":"Suppl. 1","key":"10.1016\/j.jcv.2006.09.009_bib12","first-page":"389A","article-title":"Peg interferon alfa-2a (40kDa) (Pegasys) and ribavirin (Copegus) in patients infected with HCV genotype 1 and who failed to respond to interferon and ribavirin: final results of the Spanish high dose induction pilot trial","volume":"40","author":"Diago","year":"2004","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.jcv.2006.09.009_bib13","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1086\/382279","article-title":"A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus","volume":"189","author":"Drusano","year":"2004","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.jcv.2006.09.009_bib14","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1046\/j.1365-2893.2000.00243.x","article-title":"Retreatment for 24 vs. 48 weeks with interferon-alpha2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone","volume":"7","author":"Enriquez","year":"2000","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jcv.2006.09.009_bib15","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcv.2006.09.009_bib16","series-title":"Double dose Peg-interferon alfa-2a weight-based Ribavirin improves response for Interferon\/Ribavirin non-responders with Hepatitis C: final results of RENEW study","author":"Gross","year":"2005"},{"issue":"5","key":"10.1016\/j.jcv.2006.09.009_bib17","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose","volume":"140","author":"Hadziyannis","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jcv.2006.09.009_bib18","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/00126334-200307010-00011","article-title":"The impact of hepatitis C virus coinfection on HIV progression before and after highly active antiretroviral therapy","volume":"33","author":"Klein","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jcv.2006.09.009_bib19","doi-asserted-by":"crossref","first-page":"F27","DOI":"10.1097\/00002030-200409030-00003","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV\/HCV co-infected patients","volume":"18","author":"Laguno","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.jcv.2006.09.009_bib20","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1086\/515682","article-title":"The presence of active hepatitis C virus replication in lymphoid tissue in patients coinfected with human immunodeficiency virus type 1","volume":"178","author":"Laskus","year":"1998","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jcv.2006.09.009_bib21","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jcv.2006.09.009_bib22","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1086\/367643","article-title":"Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus","volume":"36","author":"Mart\u00ednez-Sierra","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcv.2006.09.009_bib23","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1155\/2003\/131943","article-title":"High dose consensus interferon in non-responders to interferon alpha-2b and ribavirin with chronic hepatitis C","volume":"17","author":"Moskovitz","year":"2003","journal-title":"Can J Gastroenterol"},{"issue":"1","key":"10.1016\/j.jcv.2006.09.009_bib24","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00002030-200401020-00009","article-title":"Pegylated interferon alpha 2b and ribavirin in HIV\/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy","volume":"18","author":"Myers","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.jcv.2006.09.009_bib25","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1046\/j.1365-2893.2003.00427.x","article-title":"Reinforced interferon alpha-2b and ribavirin is more effective than standard combination therapy in the retreatment of chronic hepatitis C previouslynon responsive to interferon: a randomized trial","volume":"10","author":"Poynard","year":"2003","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jcv.2006.09.009_bib26","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0168-8278(02)00413-0","article-title":"A comparison of fibrosis progression in chronic liver diseases","volume":"38","author":"Poynard","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.jcv.2006.09.009_bib27","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1053\/gast.2002.33023","article-title":"Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C","volume":"122","author":"Poynard","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcv.2006.09.009_bib28","unstructured":"Roche Laboratories. NV17318, randomized, multicenter, double-blind, phase IV pilot study evaluating the effect of Pegasys\u00ae doses of 180\u03bcg or 270\u03bcg in combination with Copegus\u00ae doses of 1200mg or 1600mg on viral kinetics, virological response, pharmacokinetics, and safety in interferon-na\u00efve patients with chronic hepatitis C genotype 1 virus infection of high viral titer and body weight greater than 85kg, 2004."},{"key":"10.1016\/j.jcv.2006.09.009_bib29","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1097\/00002030-200210180-00016","article-title":"Pilot study of interferon alpha high-dose induction therapy in combination with ribavirin for chronic hepatitis C in HIV-co-infected patients","volume":"16","author":"Rockstroh","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.jcv.2006.09.009_bib30","series-title":"Proceedings of the 55th Annual meeting of the American Association for the Study of Liver Diseases","article-title":"Longer treatment duration with peginterferon alfa-2a (40kDa) (Pegasys\u00ae) and ribavirin (Copegus\u00ae) in na\u00efve patients with chronic hepatitis C and detectable HCV RNA by week 4 of therapy: final results of the randomized, multicenter Teravic-4 study","author":"Sanchez-Tapias","year":"2004"},{"key":"10.1016\/j.jcv.2006.09.009_bib31","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1128\/JCM.31.10.2679-2682.1993","article-title":"Quantitative evaluation of hepatitis C virus RNA in patients with concurrent human immunodeficiency virus infections","volume":"31","author":"Sherman","year":"1993","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jcv.2006.09.009_bib32","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1086\/339042","article-title":"Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group","volume":"34","author":"Sherman","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcv.2006.09.009_bib33","unstructured":"Soriano V. Optiming response rates to Peg\/RBV in coinfected patients: increased Ribavirin dosing; extending therapy duration. Highlights of the 2nd International Workshop on HIV and Hepatitis Coinfection, 2006."},{"issue":"4","key":"10.1016\/j.jcv.2006.09.009_bib34","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1089\/088922204323048096","article-title":"Hepatitis C virus (HCV) relapses after anti-HCV therapy are more frequent in HIV-infected patients","volume":"20","author":"Soriano","year":"2004","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"4","key":"10.1016\/j.jcv.2006.09.009_bib35","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S0168-8278(03)00298-8","article-title":"Randomized, controlled trial with IFN-alpha combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C","volume":"39","author":"Teuber","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.jcv.2006.09.009_bib36","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1023\/A:1022509304694","article-title":"Combination therapy with interferon-alpha(2b), ribavirin, and amantadine in chronic hepatitis C non-responders to interferon and ribavirin","volume":"48","author":"Thuluvath","year":"2003","journal-title":"Dig Dis Sci"},{"issue":"10","key":"10.1016\/j.jcv.2006.09.009_bib37","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1111\/j.1572-0241.2005.00222.x","article-title":"Management and treatment of hepatitis C virus infection in HIV-infected adults: recommendations from the veterans affairs hepatitis C resource center program and national hepatitis C program office","volume":"100","author":"Tien","year":"2005","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.jcv.2006.09.009_bib38","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa040842","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients","volume":"351","author":"Torriani","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcv.2006.09.009_bib39","unstructured":"World Health Organization. Hepatitis: 170 million infected worldwide and still no vaccine. WHO Press Release. No. 36. May 1, 1998."},{"issue":"Suppl. 4","key":"10.1016\/j.jcv.2006.09.009_bib40","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.3949\/ccjm.70.Suppl_4.S2","article-title":"The epidemiology and natural history of hepatitis C virus infection","volume":"70","author":"Zein","year":"2003","journal-title":"Cleve Clin J Med"}],"container-title":["Journal of Clinical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653206003453?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653206003453?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,18]],"date-time":"2020-04-18T19:21:28Z","timestamp":1587237688000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1386653206003453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["S1386653206003453"],"URL":"https:\/\/doi.org\/10.1016\/j.jcv.2006.09.009","relation":{},"ISSN":["1386-6532"],"issn-type":[{"value":"1386-6532","type":"print"}],"subject":[],"published":{"date-parts":[[2007,1]]}}}